Skip to main content

Advertisement

SpringerLink
Log in

[11C]Gefitinib ([11C]Iressa): Radiosynthesis, In Vitro Uptake, and In Vivo Imaging of Intact Murine Fibrosarcoma

  • Research Article
  • Published:
Molecular Imaging and Biology Aims and scope Submit manuscript

Abstract

Objective

Gefitinib (N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine, Iressa) is an approved anticancer drug. In this study, we labeled gefitinib with carbon-11 and evaluated [11C]gefitinib to explore its specific binding in intact fibrosarcoma (NFSa)-bearing mice.

Methods

[11C]Gefitinib was synthesized by the reaction of desmethyl precursor (1) with [11C]CH3I. In vitro uptake of [11C]gefitinib into NFSa, human-A431 epidermoid carcinoma, and Jurkat T cells was determined. Positron emission tomography (PET) imaging using [11C]gefitinib was performed for NFSa-bearing mice.

Results

[11C]Gefitinib accumulated into NFSa cells with 2.1 uptake ratio (UR)/mg protein in cells. Addition of nonradioactive gefitinib decreased uptake in a concentration-dependent manner. [11C]Gefitinib also had high uptake (2.6 UR/mg protein) into epidermal growth factor receptor/tyrosine kinase (EGFR/TK)-rich A431 cells but low uptake (0.2 UR/mg protein) into EGFR/TK-poor Jurkat cells. In vivo distribution study on NFSa-bearing mice by the dissection method revealed that [11C]gefitinib specifically accumulated into the tumor. The ratio of radioactivity in tumors to that in blood and muscle as two comparative regions increased from 0.4 to 6.0 and from 0.6 to 5.0 during this experiment (0–60 min), respectively. PET for NFSa-bearing mice produced a clear tumor image, although high radioactivity was distributed throughout the body. Treatment with nonradioactive gefitinib (100 mg/kg) decreased uptake in the tumor. In vivo metabolite analysis demonstrated that [11C]gefitinib was stable in the tumor, liver, kidney, and blood.

Conclusion

These results demonstrated the promising potential of [11C]gefitinib to serve as a PET ligand for in vivo imaging of NFSa-bearing mice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Khazaie K, Schirrmacher V, Lichtner RB (1993) EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 12:255–274

    Article  CAS  PubMed  Google Scholar 

  2. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS (1997) Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8:1197–1206

    Article  CAS  PubMed  Google Scholar 

  3. Boschelli DH (2002) 4-Anilino-3-quinolinecarbonitriles: an emerging class of kinase inhibitors. Curr Top Med Chem 2:1051–1063

    Article  CAS  PubMed  Google Scholar 

  4. Raymond E, Faivre S, Armand JP (2000) Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60(suppl 1):15–23

    Article  CAS  PubMed  Google Scholar 

  5. Ciardiello F, Caputo R, Bianco R et al (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7:1459–1465

    CAS  PubMed  Google Scholar 

  6. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL (2001) Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887–8895

    CAS  PubMed  Google Scholar 

  7. Wakeling AE, Guy SP, Woodburn JR et al (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749–5754

    CAS  PubMed  Google Scholar 

  8. Anido J, Matar P, Albanell J et al (2003) ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9:1274–1283

    CAS  PubMed  Google Scholar 

  9. Bellomi M, Petralia G, Sonzogni A, Zampino MG, Rocca A (2007) CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology 244:486–493

    Article  PubMed  Google Scholar 

  10. Søvik A, Kippenes SH, Bruland ØS, Rune OD, Malinen E (2008) DCEMRI monitoring of canine tumors during fractionated radiotherapy. Acta Oncol 47:1249–1256

    Article  PubMed  Google Scholar 

  11. Mikhaeel NG (2006) Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas. Eur J Nucl Med Mol Imaging 33(Suppl 1):22–26

    Article  PubMed  Google Scholar 

  12. Molthoff CF, Klabbers BM, Berkhof J et al (2007) Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2′-deoxy-2′-[18F]fluoro-D-glucose (FDG) and 3′-[18F]fluoro-3′-deoxythymidine (FLT). Mol Imaging Biol 9:340–347

    Article  PubMed  Google Scholar 

  13. Van de Wiele C, Lahorte C, Oyen W et al (2003) Nuclear medicine imaging to predict response to radiotherapy: a review. Int J Radiat Oncol Biol Phys 55:5–15

    Article  PubMed  Google Scholar 

  14. Riesterer O, Milas L, Ang KK (2007) Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy. J Clin Oncol 25:4075–4083

    Article  CAS  PubMed  Google Scholar 

  15. Fredriksson A, Stone-Elander S (2003) PET screening of anticancer drugs. A faster route to drug/target evaluations in vivo. Methods Mol Med 85:279–294

    CAS  PubMed  Google Scholar 

  16. Bading JR, Shields AF (2008) Imaging of cell proliferation: status and prospects. J Nucl Med 49(Suppl 2):64S–80S

    Article  CAS  PubMed  Google Scholar 

  17. Ishikawa H, Tsuji H, Kamada T et al (2006) Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer. Int J Radiat Oncol Biol Phys 66:1084–1091

    PubMed  Google Scholar 

  18. Tsuji H, Mizoe J, Kamada T et al (2007) Clinical results of carbon ion radiotherapy at NIRS. J Radiat Res 48S:A1–A13

    Article  Google Scholar 

  19. Sugane T, Baba M, Imai R et al (2009) Carbon ion radiotherapy for elderly patients 80 years and older with stage I non-small cell lung cancer. Lung Cancer 64:45–50

    Article  PubMed  Google Scholar 

  20. Zhang H, Yoshikawa K, Tamura K et al (2004) [11C]Methionine positron emission tomography and survival in patients with bone and soft tissue sarcomas treated by carbon ion radiotherapy. Clin Cancer Res 10:1764–1772

    Article  CAS  PubMed  Google Scholar 

  21. Koizumi M, Saga T, Yoshikawa K et al (2008) 11C-Methionine-PET for evaluation of carbon ion radiotherapy in patients with pelvic recurrence of rectal cancer. Mol Imaging Biol 10:374–380

    Article  PubMed  Google Scholar 

  22. Holt DP, Ravert HT, Dannals RF, Pomper MG (2006) Synthesis of [11C]gefitinib for imaging epidermal growth factor receptor tyrosine kinase with positron emission tomography. J Labelled Comp Radiopharm 49:883–888

    Article  CAS  Google Scholar 

  23. Wang JQ, Gao M, Miller KD, Sledge GW, Zheng QH (2006) Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett 16:4102–4106

    Article  CAS  PubMed  Google Scholar 

  24. DeJesus OT, Murali D, Flores LG et al (2003) Synthesis of [18F]-ZD1839 as a PET imaging agent for epidermal growth factors receptors. J Labelled Comp Radiopharm 46:s1

    Article  Google Scholar 

  25. Su H, Seimbille Y, Ferl GZ et al (2008) Evaluation of [18F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging 35:1089–1099

    Article  CAS  PubMed  Google Scholar 

  26. Ando K, Koike S, Fukuda N, Kanehira C (1984) Independent effect of a mixed-beam regimen of fast neutrons and gamma rays on a murine fibrosarcoma. Radiat Res 98:96–106

    Article  CAS  PubMed  Google Scholar 

  27. Ando K, Koike S, Ohira C et al (1999) Accelerated reoxygenation of a murine fibrosarcoma after carbon-ion radiation. Int J Radiat Biol 75:505–512

    Article  CAS  PubMed  Google Scholar 

  28. Koike S, Ando K, Oohira C et al (2002) Relative biological effectiveness of 290 MeV/u carbon ions for the growth delay of a radioresistant murine fibrosarcoma. J Radiat Res 43:247–255

    Article  PubMed  Google Scholar 

  29. Ando K, Koike S, Uzawa A et al (2005) Biological gain of carbon-ion radiotherapy for the early response of tumor growth delay and against early response of skin reaction in mice. J Radiat Res 46:51–57

    Article  PubMed  Google Scholar 

  30. Suzuki K, Inoue O, Hashimoto K, Yamasaki T, Kuchiki M, Tamate K (1985) Computer-controlled large scale production of high specific activity [11C]Ro 15–1788 for PET studies of benzodiazepine receptors. Int J Appl Radiat Isot 36:971–976

    Article  CAS  PubMed  Google Scholar 

  31. Takei M, Kida T, Suzuki K (2001) Sensitive measurement of positron emitters eluted from HPLC. Appl Radiat Isot 55:229–234

    Article  CAS  PubMed  Google Scholar 

  32. Elkind NB, Szentpetery Z, Apati A et al (2005) Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, gefitinib). Cancer Res 65:1770–1777

    Article  CAS  PubMed  Google Scholar 

  33. Mishani E, Abourbeh G, Jacobson O et al (2005) High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. J Med Chem 48:5337–5348

    Article  CAS  PubMed  Google Scholar 

  34. Pal A, Glekas A, Doubrovin M et al (2006) Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 8:262–277

    Article  CAS  PubMed  Google Scholar 

  35. Mishani E, Abourbeh G (2007) Cancer molecular imaging: radionuclide-based biomarkers of the epidermal growth factor receptor (EGFR). Curr Top Med Chem 7:1755–1772

    Article  CAS  PubMed  Google Scholar 

  36. Ghosh S, Liu XP, Zheng Y, Uckun FM (2001) Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents. Curr Cancer Drug Targets 1:129–140

    Article  CAS  PubMed  Google Scholar 

  37. Bianco R, Damiano V, Gelardi T, Daniele G, Ciardiello F, Tortora G (2007) Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. Curr Pharm Des 13:3358–3367

    Article  CAS  PubMed  Google Scholar 

  38. Press MF, Lenz HJ (2007) EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 67:2045–2075

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We are grateful to Mrs. T. Igarashi, M. Takei, and I. Nakamura (Tokyo Nuclear Service Co., Ltd.) for technical support for radiosynthesis procedures. We also thank the staff of the Cyclotron Operation Section and Department of Molecular Probes, National Institute of Radiological Sciences (NIRS) for support for the cyclotron operation and animal experiments. This study was supported in part by a Grant-in-Aid for the Molecular Imaging Program from the Ministry of Education, Culture, Sports, Science and Technology, Japanese Government.

Author information

Authors and Affiliations

  1. Department of Molecular Probes, Molecular Imaging Center, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba, Japan

    Ming-Rong Zhang, Katsushi Kumata, Akiko Hatori, Tomoteru Yamasaki, Kazuhiko Yanamoto, Joji Yui, Kazunori Kawamura & Kazutoshi Suzuki

  2. Heavy-Ion Radiobiology Research Group, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba, Japan

    Nobuhiko Takai, Sachiko Koike & Koichi Ando

  3. Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan

    Jun Toyohara

Authors
  1. Ming-Rong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katsushi Kumata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akiko Hatori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nobuhiko Takai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jun Toyohara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tomoteru Yamasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kazuhiko Yanamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Joji Yui
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kazunori Kawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sachiko Koike
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Koichi Ando
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Kazutoshi Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ming-Rong Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, MR., Kumata, K., Hatori, A. et al. [11C]Gefitinib ([11C]Iressa): Radiosynthesis, In Vitro Uptake, and In Vivo Imaging of Intact Murine Fibrosarcoma. Mol Imaging Biol 12, 181–191 (2010). https://doi.org/10.1007/s11307-009-0265-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-009-0265-5

Key words

Search

Navigation